Literature DB >> 8493752

Cytotoxic chemotherapy for advanced renal cell carcinoma.

A Yagoda1, D Petrylak, S Thompson.   

Abstract

This article reviews 72 cytotoxic chemotherapeutic agents used singly or in a limited number of two drug combinations. Results in 3502 adequately treated patients show objective response (complete and partial remissions) in only 197 or 5.6% (95% CI, 4.8% to 6.4%). Although some data suggest that a few drugs need further evaluation, at this time, renal cell carcinoma must be considered a chemotherapeutically resistant cancer.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8493752

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  39 in total

1.  A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma.

Authors:  Hui Huang; Michael Menefee; Maureen Edgerly; Sen Zhuang; Herb Kotz; Marianne Poruchynsky; Lyn Mickley Huff; Susan Bates; Tito Fojo
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

Review 2.  Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.

Authors:  E Jason Abel; Christopher G Wood
Journal:  Nat Rev Urol       Date:  2009-06-16       Impact factor: 14.432

Review 3.  Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.

Authors:  Wilfred D Stein; Hui Huang; Michael Menefee; Maureen Edgerly; Herb Kotz; Andrew Dwyer; James Yang; Susan E Bates
Journal:  Cancer J       Date:  2009 Sep-Oct       Impact factor: 3.360

4.  Systemic therapy for metastatic renal cell carcinoma: a review and update.

Authors:  Joshua E Logan; Edward N Rampersaud; Geoffrey A Sonn; Karim Chamie; Arie S Belldegrun; Allan J Pantuck; Dennis J Slamon; Fairooz F Kabbinavar
Journal:  Rev Urol       Date:  2012

Review 5.  Epigenetic regulation in RCC: opportunities for therapeutic intervention?

Authors:  James Larkin; Xin Yi Goh; Marcus Vetter; Lisa Pickering; Charles Swanton
Journal:  Nat Rev Urol       Date:  2012-01-17       Impact factor: 14.432

Review 6.  Targeted therapies for non-clear renal cell carcinoma.

Authors:  Eric A Singer; Gennady Bratslavsky; W Marston Linehan; Ramaprasad Srinivasan
Journal:  Target Oncol       Date:  2010-08-03       Impact factor: 4.493

7.  Impact of genetics on the diagnosis and treatment of renal cancer.

Authors:  Eric A Singer; Gennady Bratslavsky; Lindsay Middelton; Ramaprasad Srinivasan; W Marston Linehan
Journal:  Curr Urol Rep       Date:  2011-02       Impact factor: 3.092

Review 8.  Immunotherapy of advanced renal cell carcinoma: Current and future therapies.

Authors:  David Gill; Andrew W Hahn; Guru Sonpavde; Neeraj Agarwal
Journal:  Hum Vaccin Immunother       Date:  2016-08-05       Impact factor: 3.452

9.  Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib.

Authors:  Lauren C Harshman; Sandy Srinivas; Aya Kamaya; Benjamin I Chung
Journal:  Nat Rev Urol       Date:  2009-06       Impact factor: 14.432

10.  Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma.

Authors:  Takao Kamai; Naohisa Tomosugi; Hideyuki Abe; Kyoko Arai; Ken-Ichiro Yoshida
Journal:  BMC Cancer       Date:  2009-08-05       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.